A pharmacological analysis of stimulant-induced increases in smoking.

A pharmacological analysis of stimulant-induced increases in smoking. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A pharmacological analysis of stimulant-induced increases in smoking. Abstract Text:

Andrea R Vansickel,William W Stoops,Paul E A Glaser,Craig R Rush,

RATIONALE: Stimulants increase tobacco smoking in healthy adults under controlled laboratory conditions. The mechanisms that mediate stimulant-induced increases in smoking are not known. OBJECTIVE: The purpose of the present experiment was to characterize the pharmacological specificity of stimulant-induced increases in smoking. We tested the effects of methylphenidate and atomoxetine on smoking behavior. Atomoxetine is a norepinephrine transport inhibitor that does not increase dopamine levels in the nucleus accumbens or striatum. If stimulant-induced increases in smoking result from an additive or synergistic effect of these drugs and nicotine on dopamine levels in the nucleus accumbens or striatum, methylphenidate but not atomoxetine should increase smoking. MATERIALS AND METHODS: Doses of methylphenidate (10, 20, and 40 mg) and atomoxetine (20, 40, and 80 mg) were tested once while placebo was tested twice in 12 cigarette smokers. One hour after ingesting drug, participants smoked ad libitum for 4 h. Measures of smoking included total cigarettes, total puffs, and carbon monoxide levels. Snacks and decaffeinated drinks were available ad libitum, and food intake was calculated. RESULTS: Methylphenidate but not atomoxetine dose-dependently increased the number of cigarettes, puffs, and carbon monoxide levels. Methylphenidate and atomoxetine decreased food intake. CONCLUSIONS: The results of this experiment are consistent with the notion that stimulant-induced increases in smoking may result from an additive or synergistic effect of these drugs and nicotine on dopamine levels in the nucleus accumbens or striatum. Additional research is needed to more fully understand the pharmacological mechanisms that mediate the relationship between stimulant use and smoking.

A pharmacological analysis of stimulant-induced increases in smoking. Publishing Authors By Initials

AR Vansickel,WW Stoops,PE Glaser,CR Rush,

For similar behavior and behavior mechanisms: behavior: habits: smoking research abstracts see: behavior and behavior mechanisms: behavior: habits: smoking research

PUBMED ID PMID:

MEDLINE DATE:

A pharmacological analysis of stimulant-induced increases in smoking. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Psychopharmacology

VOLUME: 193

Page Numbers: 305-13

Journal Abbreviation: Psychopharmacology (Berl.)

ISSN: 0033-3158

DAY: 20

MONTH: 04

YEAR: 2007

A pharmacological analysis of stimulant-induced increases in smoking. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7608025

A pharmacological analysis of stimulant-induced increases in smoking. Keywords Mesh Terms:

KEYWORDS: Smoking

MESH TERMS: pharmacology

Chemical & Substance for Abstract: A pharmacological analysis of stimulant-induced increases in smoking. Information

Substance Name: atomoxetine

Registry Number: 83015-26-3

Grant and Affiliation Information for A pharmacological analysis of stimulant-induced increases in smoking.

AFFILIATION: Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, KY 40536, USA.

Country: Germany

AGENCY: United States NIDA

GRANT: DA 07304

ACRONYM: DA

MEDLINETA: Psychopharmacology (Berl)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A pharmacological analysis of stimulant-induced increases in smoking Related Publications

• A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine.
• A pharmacological analysis of stimulant-induced increases in smoking.
• Acceptability of second-step treatments to depressed outpatients: a STAR*D report.
• Accumulated Risk Factors for Lifestyle Disease in Indian Pre-Adolescent Vegetarian and Non-Vegetarian Girls: 2594: Board #141 June 2 8:00 AM - 9:30 AM.
• Bone marrow-derived cells and arterial disease.
• Bupropion in the treatment of outpatients with asthma and major depressive disorder.
• Canine pericardial effusion: diagnosis,treatment, and prognosis.
• Canine pericardial effusion: pathophysiology and cause.
• Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report.
• Customizing treatment to the patient: adaptive treatment strategies.
• Effectiveness trials in mood disorders.
• Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.
• Individual differences in drug abuse vulnerability: d-amphetamine and sensation-seeking status.
• Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression.
• Insured and non-insured depressed outpatients: how do they compare?
• Limitations in efficacy of antidepressant monotherapy.
• Lymphocyte tracking and interactions in secondary lymphoid organs.
• Pregnancy-associated congestive heart failure in a cat.
• Reconstructive options for failed flatfoot surgery.
• Reversible myocardial depression associated with sepsis in a dog.
• Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance.
• Sertraline as a first-line treatment for cholestatic pruritus.
• Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
• Substance abuse and quality of life among severely mentally ill consumers: a longitudinal modelling analysis.
• Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort.
• The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
• The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance.
• Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.
• Voltage-gated sodium channel blockers for the treatment of neuropathic pain.
• Vs02 aortic calcification: studies in patients with peripheral artery disease and a mouse model.